Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321815 | 0.97 | BTK (0.94) | BTKCLK2 | |
| SCHEMBL13894070 | 0.93 | BTK (0.88) | BTKCLK2 | |
| SCHEMBL1322755 | 0.93 | BTK (0.86) | BTKCLK2 | |
| SCHEMBL1323092 | 0.93 | BTK (0.86) | BTKCLK2 | |
| SCHEMBL1321841 | 0.92 | BTK (0.85) | BTKCLK2 | |
| SCHEMBL1322556 | 0.92 | BTK (0.85) | BTKCLK2 | |
| SCHEMBL1321862 | 0.92 | BTK (0.85) | BTKCLK2 | |
| SCHEMBL3868921 | 0.91 | BTK (1.00) | BTKCLK2 | |
| SCHEMBL1322038 | 0.91 | BTK (0.83) | BTKCLK2 | |
| SCHEMBL1323350 | 0.90 | BTK (0.82) | BTKCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081923-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2081923-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2205564-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| EP-2426109-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-18 | — | — | EP | disclosed |
| EP-2426109-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-8058446-B2 | [5-(Pyridin-2-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl]-(3-amido)-benzene derivatives; anticarcinogenic, antiproliferative, antiallergen, and antiinflammatory agents; lymphoma, leukemia, autoimmune diseases; Bruton's tyrosine kinase inhibitors | GILEAD CONNECTICUT, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058446-B2 | [5-(Pyridin-2-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl]-(3-amido)-benzene derivatives; anticarcinogenic, antiproliferative, antiallergen, and antiinflammatory agents; lymphoma, leukemia, autoimmune diseases; Bruton's tyrosine kinase inhibitors | GILEAD CONNECTICUT, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058446-B2 | [5-(Pyridin-2-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl]-(3-amido)-benzene derivatives; anticarcinogenic, antiproliferative, antiallergen, and antiinflammatory agents; lymphoma, leukemia, autoimmune diseases; Bruton's tyrosine kinase inhibitors | GILEAD CONNECTICUT, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2081923-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033854-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033854-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | BTK 1/4885CLK2 2498/4885 |
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | BTK 1/4885CLK2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.